If you enjoy this content, please share it with a colleague
Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
RELATED CONTENT
Brainlab announced the implementation of a software solution that can achieve better radiation dose conformity around brain tumors, resulting from a close strategic collaboration with Elekta. Brainlab Elements take advantage of the specific properties of Elekta’s Agility multileaf collimator and compensates for the width of selected leaves, enabling the radiation beam to more accurately conform to the tumor’s shape, thereby minimizing dose to organs at risk.
April 20, 2018 — Elekta announced that it is making a strategic investment in PalabraApps LLC to advance the development ...
Elekta announced it is collaborating with IBM Watson Health to offer Watson for Oncology with Elekta’s cancer care solutions. Under the terms of a new agreement, Elekta will sell Watson for Oncology beginning in early 2018 as a clinical decision support (CDS) solution paired within Elekta’s digital cancer care solutions, including the Mosaiq oncology information system (OIS). Elekta intends to offer both solutions in most markets around the world including the U.S., Brazil, certain major European and Asian markets, as well as India and Australia.
In establishing the new Southeast Cancer Center (Cape Girardeau, Mo.), clinic officials not only had the opportunity to offer the latest care technology and evidence-based therapies, they were also able to create a seamless, positive patient experience that supports patient healing. Essential to implementing this vision was a single, unified and universal care management system (Mosaiq OIS by Elekta) that provides all members of the multidisciplinary team the information they need, at the moment they need it, to care for every patient.
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator and Brainlab ExacTrac patient positioning and monitoring technology. The integration of these two technologies offers high-definition stereotactic radiosurgery (HDRS) treatments with versatile patient positioning and monitoring through simplified workflows. A Versa HD system augmented with ExacTrac was displayed at the Elekta booth during the American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego.
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company's magnetic resonance/radiation therapy (MR/RT) system at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego.
September 19, 2017 — Elekta will highlight its Mosaiq Oncology Analytics (MOA) software solution at the American Society ...
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at the 2017 American Association of Physicists in Medicine (AAPM) conference.
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition. The meeting is taking place July 30 - August 3 in Denver.
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain metastases, or cancerous tumors that migrate from the original location of the cancer into the brain.